In a nutshell This study investigated the safety and effectiveness of BCD-055 (BCD), a biosimilar of infliximab (IFX; Remicade). They found that the safety and effectiveness of BCD were similar to IFX. Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by painful inflammation in the joints. RA...
Read More
In a nutshell This study investigated the effectiveness of filgotinib (FGB) in patients with unresponsive rheumatoid arthritis (RA). They found that FGB improves RA management at 12 weeks. Some background Rheumatoid arthritis (RA) is a chronic condition. Inflammation leads to painful swelling in the joints. RA is treated with...
Read MoreIn a nutshell This study investigated the use of leflunomide (Arava) in juvenile idiopathic arthritis (JIA). They found that this medication may be useful in managing JIA in patients resistant or intolerant to methotrexate. Some background Juvenile idiopathic arthritis (JIA) is caused by inflammation in the joints. JIA is...
Read More
In a nutshell This study investigated if initial remission can predict long-term remission (LTR) after etanercept (Enbrel) treatment. They found that LTR is more likely if strict disease control is achieved before etanercept withdrawal Some background Rheumatoid arthritis (RA) is a long-term condition. Disease-modifying anti-rheumatic...
Read MoreIn a nutshell This study investigated the safety and effectiveness of long-term treatment with baricitinib (Olumiant) in rheumatoid arthritis (RA). They found that this drug was effective and well tolerated alone or in combination with methotrexate (MTX). Some background Rheumatoid arthritis (RA) is a long-term...
Read MoreIn a nutshell This phase 3 trial will investigate the effectiveness of GSK3196165 combined with methotrexate (MTX). The main outcome will be the number of patients achieving a 20% improvement in symptoms (ACR20). The details Rheumatoid arthritis (RA) is a condition caused by inflammation. Drugs that reduce inflammation are used to treat RA....
Read More
In a nutshell This study investigated if there is a link between frailty and fracture (breaking of a bone) risk in rheumatoid arthritis (RA). They found that patients with higher frailty were more likely to have bone fractures. Some background Rheumatoid arthritis (RA) is a chronic immune condition. It is caused by painful...
Read More
In a nutshell This study investigated the safety of abatacept (Orencia) compared to other disease-modifying anti-rheumatic drugs (DMARDs). They found that this treatment was well tolerated and had a similar safety profile to other DMARDs. Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by painful swelling...
Read More
In a nutshell This study investigated the effectiveness of methotrexate (MTX) versus tocilizumab (TCZ) in early rheumatoid arthritis (RA). They found that TCZ patients had a greater reduction in disease activity (DA). Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by excessive inflammation...
Read More
In a nutshell This study investigated the rates of orofacial symptoms (OFS) and dentofacial deformities (DFD) in patients with juvenile idiopathic arthritis (JIA). They found that OFS and DFD rates were high in JIA. Some background Juvenile idiopathic arthritis (JIA) is an inflammatory condition that affects children. JIA leads to painful...
Read More
In a nutshell This study investigated if bimekizumab and certolizumab pegol (Cimzia) is a safe and effective treatment combination in rheumatoid arthritis (RA). They found that this treatment combination improved RA symptoms and was well tolerated. Some background Rheumatoid arthritis (RA) is a chronic inflammatory...
Read More
In a nutshell This study investigated the effectiveness of medication tapering strategies in rheumatoid arthritis (RA). They found that tapering synthetic or biologic drugs was similarly effective. Some background Rheumatoid arthritis (RA) is a long-term immune condition. It is caused by painful swelling in the joints. Disease-modifying...
Read More
